The Dana-Farber/Harvard Cancer Center (DF/HCC) is an innovative collaboration formed in 1999 from the original Dana-Farber Cancer Center, which had been designated by the National Cancer Institute (NCI) as a Comprehensive Cancer Center, and has been supported by the NCI for the past 36 years. DF/HCC was formally funded as a 7-institution consortium, including the Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital, and an NCI-designated Comprehensive Cancer Center in 2000. The cancer research and treatment collaborations sponsored across participating institutions by the DF/HCC combine the disciplines of population science, clinical science, and basic research to facilitate the development of novel and improved modalities for the prevention and treatment of cancer.